Medexus to Present at MicroCap Rodeo Best Ideas Bowl on October 14th

MONTREAL, QC / ACCESSWIRE / October 7, 2020 / Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP)(OTCQX:MEDXF) today announced that it will be presenting at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th - 16th, 2020.

Ken d'Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer of Medexus are scheduled to present on Wednesday, October 14^th at 12:30 p.m., Eastern Time. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2134/37963. One-on-one meetings will be held throughout the conference via video conference calls.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email Angie.Goertz@IssuerDirect.com.

About the MicroCap Rodeo Best Ideas Bowl

The MicroCap Rodeo is back with its first ever "Best Ideas Bowl." This conference is a virtual conference that brings you the top 25 best ideas from the buy side. Qualified institutional investors recommended each of the 25 companies represented as one of their best ideas. For more information please visit our website: https://microcaprodeo.com/.

About Medexus

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy. The Company's leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B - a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative allergy medication with a unique mode of action.

For more information, please contact:

Ken d'Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: ken.dentremont@medexus.com

Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-762-2626 ext. 202
E-mail: roland.boivin@medexus.com

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Email: mdp@crescendo-ir.com

Investor Relations (Canada):
Tina Byers
Adelaide Capital

Tel: 905-330-3275
E-mail: tina@adcap.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Medexus Pharmaceuticals Inc.

Released October 7, 2020